BridgeBio CEO Neil Kumar at BIO22 (J.T. MacMillan Photography for Endpoints News)

February 7, 2024 04:01 AM ESTUpdated 08:39 AM

Updated: BridgeBio inks $100M upfront deal with Kyowa Kirin for skeletal disorder drug

Kyle LaHucik

Senior Reporter

BridgeBio will pocket $100 million as it partners with Japanese pharma Kyowa Kirin to explore the use of infigratinib in several skeletal disorders, the companies …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: BridgeBio inks $100M upfront deal with Kyowa Kirin for skeletal disorder drug

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Halozyme withdraws Evotec acquisition proposal after biotech is 'unwilling to engage'

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Are programs with compounded GLP-1s safe for your population?

Up­dat­ed: Bridge­Bio inks $100M up­front deal with Ky­owa Kirin for skele­tal dis­or­der drug

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Updated: BridgeBio inks $100M upfront deal with Kyowa Kirin for skeletal disorder drug

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Halozyme withdraws Evotec acquisition proposal after biotech is 'unwilling to engage'

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Are programs with compounded GLP-1s safe for your population?